NTLA

Insider Trades

Name	Value	Action	Price	Current Price
Basta JamesEVP, General Counsel $17k1.2k shares SellMar 2, 2026 $13.78 --
Clark ElianaEVP, Chief Technical Officer $8.4k607 shares SellMar 2, 2026 $13.78 --
Cohen Fred EDirector $1.4M150k shares BuyJan 5, 2026 $9.35 --
Leonard John MDirector, Officer: President And CEO $314k34.1k shares SellJan 5, 2026 $9.21 --
Lebwohl DavidEVP, Chief Medical Officer $110k11.9k shares SellJan 5, 2026 $9.21 --
Basta JamesEVP, General Counsel $96k10.4k shares SellJan 5, 2026 $9.21 --

News

globenewswire.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.comJun 5

globenewswire.comIntellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026globenewswire.comJun 1

seekingalpha.comIntellia Therapeutics - Steady Progress, Historic Commercial Approval In Sightseekingalpha.comMay 31

zacks.comADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?zacks.comMay 27

zacks.comCan Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?zacks.comMay 19

Trade NTLA

About Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

CEO: John Leonard
IPO Date: May 6, 2016

Market Data

Open: $13.77
High: $14.25
Low: $13.30
Volume: 1.2M
52W High: $28.25
52W Low: $7.95

Valuation

Market Cap: $1.5B
Enterprise Value: $1.4B

Financials

Free Cash Flow: $-355M
Revenue: $68M
Net Income: $-413M
Cash: $155M
Debt: $93M

Events

EarningsAug 6

EPS est. -0.8